VTE治疗中新型口服抗凝药物的选择L.CN.MKT.02.2018.5125在整堂课的教学中，刘教师总是让学生带着问题来学习，而问题的设置具有一定的梯度，由浅入深，所提出的问题也很明确ACCP10指南推荐：VTE治疗，NOACs优于VKA/LWMHNOACs降低VTE复发风险与VKA相似NOACs对患者及医生的便利性优于VKANOACs出血风险低于VKA疗效简便性安全性Kearon C, et al. Chest. 2016;149(2):315-52.For VTE and no cancer, as long-term anticoagulant therapy, we suggest dabigatran (Grade 2B), rivaroxaban (Grade 2B), apixaban (Grade 2B), or edoxaban (Grade 2B) over vitamin K antagonist (VKA) therapy, and suggest VKA therapy over low-molecular-weight heparin (LMWH; Grad
